Yes, Ipilimumab Is Approved for Use with Opdivo
Ipilimumab (Yervoy) and Opdivo (nivolumab) are combined in FDA-approved regimens for cancers including melanoma, renal cell carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, gastric cancer, and malignant pleural mesothelioma. The combo targets CTLA-4 (ipilimumab) and PD-1 (nivolumab) to boost immune response against tumors.[1][2]
Common Dosing Schedules
Typical regimens use nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks for four doses, followed by nivolumab 480 mg every 4 weeks. Doses adjust by cancer type and patient weight; for example, fixed doses like nivolumab 240 mg every 2 weeks with ipilimumab 1 mg/kg every 6 weeks apply in some melanoma cases.[2][3]
Which Cancers Get the Combo
| Cancer Type | Key Approval Notes |
|-------------|-------------------|
| Unresectable or metastatic melanoma | First-line standard; improves survival over monotherapy.[2] |
| Intermediate/poor-risk advanced renal cell carcinoma | With or after surgery; first-line option.[2] |
| MSI-H or dMMR metastatic colorectal cancer | After fluoropyrimidine failure.[2] |
| Unresectable hepatocellular carcinoma | First-line with or without surgery.[2] |
| Esophageal squamous cell carcinoma | First-line advanced cases.[2] |
| Gastric/GEJ/esophageal adenocarcinoma | First-line HER2-negative metastatic.[2] |
| Malignant pleural mesothelioma | First-line unresectable.[2] |
How the Combination Works
Nivolumab blocks PD-1 to release T-cell brakes, while ipilimumab targets CTLA-4 earlier in activation. Together, they enhance antitumor activity more than either alone, based on trials like CheckMate 067 showing doubled progression-free survival in melanoma.[3][4]
Side Effects Patients Report Most
Immune-related adverse events hit 96% in combo trials, versus 86% with nivolumab alone. Common issues include fatigue (62%), rash (58%), pruritus (52%), diarrhea (50%), and nausea (44%). Severe (grade 3/4) events like colitis (12%), hepatitis (8%), and endocrinopathies (20%) often need steroids or treatment holds.[2][4] Patients ask about thyroid issues, skin reactions, and long-term monitoring.
Differences from Using Opdivo Alone
Combo boosts response rates (e.g., 58% vs. 44% objective response in melanoma) and overall survival but doubles severe toxicity risk. Monotherapy suits lower-risk patients or those intolerant to dual therapy.[3][4]
Who Makes Them and Patent Status
Bristol Myers Squibb manufactures both. Opdivo patents expire around 2033-2038 in the US; ipilimumab's around 2028-2032, with ongoing challenges. Biosimilars unlikely before 2028.[5]
Sources
[1]: FDA Opdivo Label
[2]: FDA Yervoy Label
[3]: CheckMate 067 Trial (NEJM)
[4]: CheckMate 214 RCC Trial (NEJM)
[5]: DrugPatentWatch.com - Nivolumab | DrugPatentWatch.com - Ipilimumab